Notice: OncosilTM is currently unapproved in all jurisdictions
Transforming the prognosis
OncoSilTM is a brachytherapy device that implants a pre-determined dose of beta radiation. The beta particles emitted by OncoSilTM travel a short distance in tissue causing damage to targeted cell DNA, which renders them incapable of further cell division and proliferation.
OncoSil Medical is currently undertaking clinical studies to investigate the clinical benefit of the addition of OncoSilTM when combined with standard of care chemotherapies in the pancreas.
OncoSil Medical Ltd has developed a new technology - Phosphorous-32 Microparticles suspended in Diluent.
This product is called OncoSilTM and is an active implantable (radiological) medical device injected during an Endoscopic Ultrasound (EUS) guidance procedure.
Oncosil Medical is a Sydney based medical device company focused on Interventional Oncology in the pancreas and liver. Oncosil Medical has developed a medical device called OncosilTM and is progressing towards product commercialisation.
The device is currently undergoing clinical studies globally. The clinical data will be used for regulatory submissions in the EU, USA, Australia and Asia.